Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 1999

View Archived Issues

SmithKline Beecham scientists identify urotensin-II receptor

Wyeth-Ayerst provides updated information on stroke Rx

UT researchers uncover mechanism of chemopreventive activity of sulindac

First patient receives transplanted porcine fetal neural cells in Diacrin's phase I study

New interferon inducers described by Sumitomo and Japan Energy

Tanabe Seiyaku presents PAI-1 inhibitors as antithrombotics

Anilines from Yamanouchi exert selective inhibition of CRACC

Phase I results of Bay-12-9566 presented at ECCO 10; Bayer halts all trials on the compound

Kanebo discloses preparation and use of new selectin inhibitors

French investigators continue research on homocamptothecins; dual Topo I and II inhibitor identified

Chinese researchers design new norcantharidinimide derivatives as antitumor agents

New hematoporphyrins for photodynamic therapy of tumors in development in China

Blockade of terminal 5-HT autoreceptor by selective 5-HT1B receptor inverse agonist SB-236057

TriAb prolongs disease progression in breast cancer patients

Significant efficacy, minimal toxicity reported for radiosensitizing agent AK-2123

Roche's breakthrough flu treatment approved in Switzerland

Latest results with RWJ-54428/MC-02479 presented at ICAAC

Dual NEP/ACE inhibitor attenuates left ventricular remodeling without affecting blood pressure

FDA approves Santen's Alamast for prevention of itchy eyes due to allergic conjunctivitis

Progen initiates phase I trial of anticancer drug PI-88

PST-2107, an Na+/K+-ATPase inhibitor with significant advantages over digoxin

Purdue Pharma completes tender offer for CoCensys

New oral cephalosporin from LG Chemical shows promise for Rx of respiratory tract infections

CollaGenex and Merck establish copromotion agreement for Vioxx

Shareholders approve Corixa's acquisition of Ribi

News from ICAAC: Microcide presents anti-MRSA 3-heteroarylthio cephem and its prodrug

Novel Na+/H+ exchange inhibitor presented at Japanese congress

FDA informs Aronex that Atragen NDA is not approvable

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...